{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:05:14Z","timestamp":1790687114637,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100001358","name":"Sun Health Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001358","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s12325-021-01971-9","type":"journal-article","created":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T03:02:18Z","timestamp":1639710138000},"page":"923-942","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase\u00a0III Study"],"prefix":"10.1007","volume":"39","clinical-trial-number":[{"clinical-trial-number":"ctri\/2016\/11\/007491","registry":"10.18810\/clinical-trial-registry-india"}],"author":[{"given":"Gouranga","family":"Sarkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay B.","family":"Gaikwad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aradhana","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapan K.","family":"Halder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darivemula A.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitendra","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash","family":"Kumbhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhushan","family":"Kinholkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishabh","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maulik","family":"Doshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Bachani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyog","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,17]]},"reference":[{"key":"1971_CR1","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(08)60655-8","volume":"371","author":"CM Lawes","year":"2008","unstructured":"Lawes CM, Vander Hoorn S, Rodgers A, International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513\u20138.","journal-title":"Lancet"},{"key":"1971_CR2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s11906-013-0340-9","volume":"15","author":"S Bromfield","year":"2013","unstructured":"Bromfield S, Muntner P. High blood pressure: the leading global burden of disease risk factor and the need for worldwide prevention programs. Curr Hypertens Rep. 2013;15:134\u20136.","journal-title":"Curr Hypertens Rep"},{"key":"1971_CR3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ihj.2019.09.012","volume":"71","author":"R Sivasubramanian","year":"2019","unstructured":"Sivasubramanian R, Geevar Z, Kartik G, et al. Prevalence of hypertension among Indian adults: results from the great India blood pressure survey. Indian Heart J. 2019;71:309\u201313.","journal-title":"Indian Heart J"},{"key":"1971_CR4","doi-asserted-by":"crossref","unstructured":"Sharma VK, Minolin M. Assess the prevalence and risk factor of hypertension among the adult at mandrail in Rajasthan. IJSR. 2015;6:2459\u20132461.","DOI":"10.21275\/ART20164213"},{"key":"1971_CR5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002801","volume":"16","author":"J Prenissl","year":"2019","unstructured":"Prenissl J, Manne-Goehler J, Jaacks LM, et al. Hypertension screening, awareness, treatment, and control in India: a nationally representative cross-sectional study among individuals aged 15 to 49 years. PLoS Med. 2019;16:e1002801.","journal-title":"PLoS Med"},{"key":"1971_CR6","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","volume":"360","author":"S Lewington","year":"2002","unstructured":"Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903\u201313 (Erratum in: Lancet. 2003;361(9362):1060).","journal-title":"Lancet"},{"key":"1971_CR7","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/jamacardio.2017.1421","volume":"2","author":"JD Bundy","year":"2017","unstructured":"Bundy JD, Li C, Stuchlik P, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol. 2017;2:775\u201381.","journal-title":"JAMA Cardiol"},{"key":"1971_CR8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.phrs.2017.10.003","volume":"128","author":"C Cuspidi","year":"2018","unstructured":"Cuspidi C, Tadic M, Grassi G, Mancia G. Treatment of hypertension: the ESH\/ESC guidelines recommendations. Pharmacol Res. 2018;128:315\u201321.","journal-title":"Pharmacol Res"},{"issue":"11 Suppl. 4","key":"1971_CR9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1524-6175.2007.07724.x","volume":"9","author":"SD Nesbitt","year":"2007","unstructured":"Nesbitt SD. Antihypertensive combination therapy: optimizing blood pressure control and cardiovascular risk reduction. J Clin Hypertens. 2007;9(11 Suppl. 4):26\u201332.","journal-title":"J Clin Hypertens"},{"key":"1971_CR10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1524-6175.2002.02045.x","volume":"4","author":"WC Cushman","year":"2002","unstructured":"Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American Settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens. 2002;4:393\u2013404.","journal-title":"J Clin Hypertens"},{"key":"1971_CR11","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","volume":"351","author":"L Hansson","year":"1998","unstructured":"Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood\u2013pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet. 1998;351:1755\u201362.","journal-title":"Lancet"},{"key":"1971_CR12","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1001\/jama.289.16.2073","volume":"289","author":"HR Black","year":"2003","unstructured":"Black HR, Elliot WJ, Grandits G, et al. Principal results of the Controlled Onset Verapramil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289:2073\u201382.","journal-title":"JAMA"},{"key":"1971_CR13","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahlof","year":"2002","unstructured":"Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in Hypertensive Study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995\u20131003.","journal-title":"Lancet"},{"key":"1971_CR14","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJM199304013281303","volume":"328","author":"BJ Materson","year":"1993","unstructured":"Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 1993;328:914\u201321.","journal-title":"N Engl J Med"},{"key":"1971_CR15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/00003495-200262030-00003","volume":"62","author":"DA Sica","year":"2002","unstructured":"Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs. 2002;62:443\u201362.","journal-title":"Drugs"},{"key":"1971_CR16","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/s41371-020-0349-x","volume":"34","author":"SN Shah","year":"2020","unstructured":"Shah SN, Munjal YP, Kamath SA, et al. Indian guidelines on hypertension-IV (2019). J Hum Hypertens. 2020;34:745\u201358.","journal-title":"J Hum Hypertens"},{"key":"1971_CR17","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2147\/VHRM.S11522","volume":"6","author":"M Destro","year":"2010","unstructured":"Destro M, Crikelair N, Yen J, Glazer R. Triple combination therapy with amlodipine, valsartan, and hydrochlorothiazide vs dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients. Vascular Health Risk Manag. 2010;6:821.","journal-title":"Vascular Health Risk Manag"},{"issue":"5","key":"1971_CR18","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1161\/HYP.0000000000000087","volume":"73","author":"P Muntner","year":"2019","unstructured":"Muntner P, Shimbo D, Carey RM, et al. Measurement of blood pressure in humans: a scientific statement from the American Heart Association. Hypertension. 2019;73(5):e35\u201366. https:\/\/doi.org\/10.1161\/HYP.0000000000000087.","journal-title":"Hypertension"},{"key":"1971_CR19","first-page":"1098","volume":"240","author":"S Joshi","year":"2017","unstructured":"Joshi S. Salt sensitivity in hypertension. API Textbook Medi Update. 2017;240:1098\u2013103.","journal-title":"API Textbook Medi Update"},{"issue":"8","key":"1971_CR20","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1097\/HJH.0000000000002088","volume":"37","author":"M Burnier","year":"2019","unstructured":"Burnier M, Bakris G, Williams B. Redefining diuretics use in hypertension: why select a thiazide-like diuretic? J Hypertens. 2019;37(8):1574\u201386.","journal-title":"J Hypertens"},{"key":"1971_CR21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jch.13426","volume":"21","author":"DJ DiPette","year":"2019","unstructured":"DiPette DJ, Skeete J, Ridley E, et al. Fixed-dose combination pharmacologic therapy to improve hypertension control worldwide: clinical perspective and policy implications. J Clin Hypertens (Greenwich). 2019;21:4\u201315.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1971_CR22","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, et al. National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560\u201372.","journal-title":"JAMA"},{"key":"1971_CR23","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1001\/archinte.161.22.2661","volume":"161","author":"GL Bakris","year":"2001","unstructured":"Bakris GL. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med. 2001;161:2661\u20137.","journal-title":"Arch Intern Med"},{"key":"1971_CR24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1161\/01.HYP.37.1.12","volume":"37","author":"HR Black","year":"2001","unstructured":"Black HR, Elliott WJ, Neaton JD, et al. Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension. 2001;37:12\u20138.","journal-title":"Hypertension"},{"issue":"6","key":"1971_CR25","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1524-6175.2002.02045.x","volume":"4","author":"WC Cushman","year":"2002","unstructured":"Cushman WC, Ford CE, Cutler JA, et al. ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4(6):393\u2013404.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1971_CR26","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, et al. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth Joint National Committee (JNC 8). JAMA. 2014;311:507\u201320.","journal-title":"JAMA"},{"key":"1971_CR27","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.cjca.2018.02.022","volume":"34","author":"KA Nerenberg","year":"2018","unstructured":"Nerenberg KA, Zarnke KB, Leung AA, et al. Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children. Can J Cardiol. 2018;34:506\u201325.","journal-title":"Can J Cardiol"},{"key":"1971_CR28","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ahj.2011.05.010","volume":"162","author":"JB Byrd","year":"2011","unstructured":"Byrd JB, Zeng C, Tavel HM, et al. Combination therapy as initial treatment for newly diagnosed hypertension. Am Heart J. 2011;162:340\u20136.","journal-title":"Am Heart J"},{"key":"1971_CR29","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3109\/10641960903265212","volume":"32","author":"R Fogari","year":"2010","unstructured":"Fogari R, Zoppi A, Ferrari I, Mugellini A, Preti P, Derosa G. Time to achieve blood pressure goal with a combination versus a conventional monotherapy approach in hypertensive patients with metabolic syndrome. Clin Exp Hypertens. 2010;32:245\u201350.","journal-title":"Clin Exp Hypertens"},{"key":"1971_CR30","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1161\/HYPERTENSIONAHA.112.201566","volume":"61","author":"AH Gradman","year":"2013","unstructured":"Gradman AH, Paris\u00e9 H, Lefebvre P, Falvey H, Lafeuille MH, Duh MS. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension. 2013;61:309\u201318.","journal-title":"Hypertension"},{"key":"1971_CR31","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","volume":"122","author":"DS Wald","year":"2009","unstructured":"Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122:290\u2013300.","journal-title":"Am J Med"},{"key":"1971_CR32","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jash.2010.03.001","volume":"4","author":"AH Gradman","year":"2010","unstructured":"Gradman AH, Basile JN, Carter BL, et al. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4:90\u20138.","journal-title":"J Am Soc Hypertens"},{"key":"1971_CR33","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","volume":"317","author":"R Turner","year":"1998","unstructured":"Turner R, Matthews D, Neil A, Mcelroy H. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703\u201313.","journal-title":"BMJ"},{"key":"1971_CR34","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(05)79282-5","volume":"352","author":"JM Cruickshank","year":"1998","unstructured":"Cruickshank JM. Hypertension optimal treatment (HOT) trial. Lancet. 1998;352:573\u20134.","journal-title":"Lancet"},{"key":"1971_CR35","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","unstructured":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288:2981\u201397.","journal-title":"JAMA"},{"key":"1971_CR36","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/CIRCULATIONAHA.110.960120","volume":"122","author":"G Mancia","year":"2010","unstructured":"Mancia G. Effects of intensive blood pressure control in the management of patients with type 2 diabetes mellitus in the action to control cardiovascular risk in diabetes (ACCORD) trial. Circulation. 2010;122:847\u20139.","journal-title":"Circulation"},{"issue":"21","key":"1971_CR37","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1600175","volume":"374","author":"EM Lonn","year":"2016","unstructured":"Lonn EM, Bosch J, L\u00f3pez-Jaramillo P, et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374(21):2009\u201320.","journal-title":"N Engl J Med"},{"key":"1971_CR38","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright","year":"2015","unstructured":"SPRINT Research Group, Wright JT, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103\u201316.","journal-title":"N Engl J Med"},{"key":"1971_CR39","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","volume":"359","author":"K Jamerson","year":"2008","unstructured":"Jamerson K, Weber MA, Bakris GL, et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417\u201328.","journal-title":"N Engl J Med"},{"key":"1971_CR40","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","volume":"363","author":"S Julius","year":"2004","unstructured":"Julius S, Kjeldsen SE, Weber M, et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022\u201331.","journal-title":"Lancet"},{"key":"1971_CR41","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","volume":"370","author":"A Patel","year":"2007","unstructured":"Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829\u201340.","journal-title":"Lancet"},{"key":"1971_CR42","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","volume":"358","author":"PROGRESS Collaborative Group","year":"2001","unstructured":"PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033\u201341.","journal-title":"Lancet"},{"issue":"33","key":"1971_CR43","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension [published correction appears in Eur Heart J. 2019 Feb 1;40(5):475]. Eur Heart J. 2018;39(33):3021\u2013104.","journal-title":"Eur Heart J"},{"key":"1971_CR44","first-page":"35","volume":"57","author":"M Panja","year":"2009","unstructured":"Panja M, Mondal S, Bhattacharya P, Mondal D. \u03b2-blocker in combination with other antihypertensives. J Assoc Physicians India. 2009;57:35\u20137.","journal-title":"J Assoc Physicians India"},{"key":"1971_CR45","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/jamacardio.2020.2739","volume":"5","author":"N Wang","year":"2020","unstructured":"Wang N, Salam A, Webster R, et al. TRIUMPH Study Group. Association of low-dose triple combination therapy with therapeutic inertia and prescribing patterns in patients with hypertension: a secondary analysis of the TRIUMPH trial. JAMA Cardiol. 2020;5:1219\u201326.","journal-title":"JAMA Cardiol"},{"key":"1971_CR46","first-page":"687","volume":"7","author":"SV Sagarad","year":"2013","unstructured":"Sagarad SV, Kerure SB, Kumar SC, Mr R. The antihypertensive efficacy of chlorthalidone and telmisartan in indian hypertensive patients who were uncontrolled with hydrochlorothiazide and telmisartan combination\u2014a prospective and an open label study. J Clin Diagn Res. 2013;7:687\u201390.","journal-title":"J Clin Diagn Res"},{"key":"1971_CR47","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/2047-783X-14-7-297","volume":"14","author":"A Pareek","year":"2009","unstructured":"Pareek A, Zawar D, Salagre SB, et al. Antihypertensive efficacy of metoprolol extended release xl\/low dose chlorthalidone (6.25 mg) combination: a randomized, comparative study in Indian subjects with mild-to-moderate essential hypertension. Eur J Med Res. 2009;14:297\u2013303.","journal-title":"Eur J Med Res"},{"key":"1971_CR48","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1345\/aph.1C393","volume":"37","author":"PM Finnegan","year":"2003","unstructured":"Finnegan PM, Gleason BL. Combination ACE inhibitors and angiotensin II receptor blockers for hypertension. Ann Pharmacother. 2003;37:886\u20139.","journal-title":"Ann Pharmacother"},{"key":"1971_CR49","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1524-6175.2003.02836.x","volume":"5","author":"DA Sica","year":"2003","unstructured":"Sica DA. Combination angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy: its role in clinical practice. J Clin Hypertens (Greenwich). 2003;5:414\u201320.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1971_CR50","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/ajh\/hpt035","volume":"26","author":"SH Hong","year":"2013","unstructured":"Hong SH, Wang J, Tang J. Dynamic view on affordability of fixed dose combination antihypertensive drug therapy. Am J Hypertens. 2013;26:879\u201387.","journal-title":"Am J Hypertens"},{"key":"1971_CR51","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/1753944709356012","volume":"4","author":"J Basile","year":"2010","unstructured":"Basile J, Neutel J. Overcoming clinical inertia to achieve blood pressure goals: the role of fixed-dose combination therapy. Ther Adv Cardiovasc Dis. 2010;4:119\u201327.","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"1971_CR52","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/jch.13035","volume":"19","author":"Y-C Tung","year":"2017","unstructured":"Tung Y-C, Huang Y-C, Wu L-S, Chang C-J, Chu P-H. Medication compliance and clinical outcomes of fixed-dose combinations vs free combinations of an angiotensin II receptor blocker and a calcium channel blocker in hypertension treatment. J Clin Hypertens. 2017;19:983\u20139.","journal-title":"J Clin Hypertens"},{"key":"1971_CR53","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/jch.13299","volume":"20","author":"S Satsoglou","year":"2018","unstructured":"Satsoglou S, Tziomalos K. Fixed-dose combinations: a valuable tool to improve adherence to antihypertensive treatment. J Clin Hypertens. 2018;20:908\u20139.","journal-title":"J Clin Hypertens"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01971-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01971-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01971-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T10:44:30Z","timestamp":1699958670000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01971-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,17]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1971"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01971-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,17]]},"assertion":[{"value":"20 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}